0001437749-21-016573.txt : 20210707 0001437749-21-016573.hdr.sgml : 20210707 20210707162944 ACCESSION NUMBER: 0001437749-21-016573 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210702 FILED AS OF DATE: 20210707 DATE AS OF CHANGE: 20210707 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEAVER GREGORY L CENTRAL INDEX KEY: 0001251779 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 211077728 MAIL ADDRESS: STREET 1: 185 BERRY STREET STREET 2: SUITE 6504 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 FORMER COMPANY: FORMER CONFORMED NAME: ATOSSA GENETICS INC DATE OF NAME CHANGE: 20100325 4 1 rdgdoc.xml FORM 4 X0306 4 2021-07-02 0001488039 ATOSSA THERAPEUTICS, INC. ATOS 0001251779 WEAVER GREGORY L C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET SEATTLE WA 98104 1 Common Stock 2021-07-02 4 M 0 4581 5.64 A 4581 D Common Stock 2021-07-02 4 M 0 45000 2.38 A 49581 D Common Stock 2021-07-02 4 M 0 45000 2.52 A 94581 D Common Stock 2021-07-02 4 M 0 70000 1.70 A 164581 D Common Stock 2021-07-02 4 F 0 57084 6.40 D 107497 D Common Stock 2021-07-02 4 S 0 107497 5.58 D 0 D Stock Option (right to buy) 5.64 2021-07-02 4 M 0 4581 0 D Common Stock 4581 0 D Stock Option (right to buy) 2.38 2021-07-02 4 M 0 45000 0 D Common Stock 45000 0 D Stock Option (right to buy) 2.52 2021-07-02 4 M 0 45000 0 D Common Stock 45000 0 D Stock Option (right to buy) 1.70 2021-07-02 4 M 0 70000 0 D Common Stock 70000 0 D Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021. Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date. These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date. These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date. These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date. /s/ Gregory L. Weaver 2021-07-07